JP2017514787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514787A5 JP2017514787A5 JP2016553489A JP2016553489A JP2017514787A5 JP 2017514787 A5 JP2017514787 A5 JP 2017514787A5 JP 2016553489 A JP2016553489 A JP 2016553489A JP 2016553489 A JP2016553489 A JP 2016553489A JP 2017514787 A5 JP2017514787 A5 JP 2017514787A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- april
- composition
- variant
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000021161 Plasma cell disease Diseases 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 208000007452 Plasmacytoma Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 102000001493 Cyclophilins Human genes 0.000 claims description 2
- 108010068682 Cyclophilins Proteins 0.000 claims description 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims description 2
- 208000025750 heavy chain disease Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 12
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 239000004333 gold (food color) Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1403481.3 | 2014-02-27 | ||
| GB201403479A GB201403479D0 (en) | 2014-02-27 | 2014-02-27 | Molecule |
| GB201403481A GB201403481D0 (en) | 2014-02-27 | 2014-02-27 | Chimeric antigen receptor |
| GB1403479.7 | 2014-02-27 | ||
| GB1409761.2 | 2014-06-02 | ||
| GB1409759.6 | 2014-06-02 | ||
| GB201409759A GB201409759D0 (en) | 2014-06-02 | 2014-06-02 | Molecule |
| GB201409761A GB201409761D0 (en) | 2014-06-02 | 2014-06-02 | Chimeric antigen receptor |
| PCT/GB2015/050557 WO2015128653A2 (en) | 2014-02-27 | 2015-02-26 | Ligand |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107701A Division JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Division JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514787A JP2017514787A (ja) | 2017-06-08 |
| JP2017514787A5 true JP2017514787A5 (enExample) | 2018-02-15 |
| JP6556156B2 JP6556156B2 (ja) | 2019-08-07 |
Family
ID=52633311
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553489A Expired - Fee Related JP6556156B2 (ja) | 2014-02-27 | 2015-02-26 | Ａｐｒｉｌバリアント |
| JP2017107701A Expired - Fee Related JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Pending JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107701A Expired - Fee Related JP6707496B2 (ja) | 2014-02-27 | 2017-05-31 | Ａｐｒｉｌバリアント |
| JP2019014039A Pending JP2019068855A (ja) | 2014-02-27 | 2019-01-30 | Ａｐｒｉｌバリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10752665B2 (enExample) |
| EP (2) | EP3110838B1 (enExample) |
| JP (3) | JP6556156B2 (enExample) |
| CN (1) | CN106414502A (enExample) |
| AU (1) | AU2015221933B2 (enExample) |
| CA (1) | CA2939411A1 (enExample) |
| ES (1) | ES2737690T3 (enExample) |
| WO (1) | WO2015128653A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| AU2015221933B2 (en) | 2014-02-27 | 2019-09-12 | Autolus Limited | APRIL variants |
| US11253546B2 (en) | 2014-12-15 | 2022-02-22 | The Regents Of The University Of California | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 |
| KR102528825B1 (ko) | 2015-04-13 | 2023-05-08 | 화이자 인코포레이티드 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| CN109641012A (zh) * | 2016-06-07 | 2019-04-16 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 与bcma结合的嵌合抗原受体和car-t细胞 |
| WO2018042385A2 (en) | 2016-09-02 | 2018-03-08 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| CN108277205B (zh) * | 2016-12-30 | 2022-12-20 | 四川大学 | 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途 |
| JP2021500882A (ja) * | 2017-10-18 | 2021-01-14 | プレシゲン，インコーポレイテッド | スペーサーを含むポリペプチド組成物 |
| EP3704157A1 (en) | 2017-11-01 | 2020-09-09 | Hummingbird Bioscience Holdings Pte. Ltd. | Cd47 antigen-binding molecules |
| GB201720426D0 (en) * | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
| JP7566628B2 (ja) * | 2018-01-10 | 2024-10-15 | ザ ジェネラル ホスピタル コーポレイション | キメラ抗原受容体を発現する免疫細胞 |
| CN112533942A (zh) | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
| CN112566643A (zh) * | 2018-06-12 | 2021-03-26 | 加利福尼亚大学董事会 | 用于治疗癌症的单链双特异性嵌合抗原受体 |
| CN114206919B (zh) * | 2019-06-04 | 2025-07-15 | 综合医院公司 | 靶向taci的抗体和嵌合抗原受体 |
| CN110642953B (zh) * | 2019-10-12 | 2021-09-17 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向bcma的t细胞受体融合蛋白和应用 |
| CA3227108A1 (en) | 2021-08-11 | 2023-02-16 | Xiaomeng HU | Genetically modified primary cells for allogeneic cell therapy |
| US20250127820A1 (en) | 2021-08-11 | 2025-04-24 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| EP4384544A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| JP2024534771A (ja) | 2021-08-11 | 2024-09-26 | サナ バイオテクノロジー，インコーポレイテッド | 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞 |
| WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2024097315A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Cell therapy products and methods for producing same |
| WO2025043172A1 (en) | 2023-08-23 | 2025-02-27 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| AU2048501A (en) * | 2000-02-16 | 2001-08-27 | Genentech Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| WO2004020593A2 (en) | 2002-08-30 | 2004-03-11 | Incyte Corporation | Immune response associated proteins |
| WO2004089982A2 (en) * | 2003-01-06 | 2004-10-21 | Xencor | April variants and methods thereof |
| US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20050003480A1 (en) * | 2003-01-06 | 2005-01-06 | Xencor | April variants and methods thereof |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
| CA2833820C (en) | 2011-05-27 | 2019-10-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| HK1203393A1 (en) | 2012-04-11 | 2015-10-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| AU2015221933B2 (en) | 2014-02-27 | 2019-09-12 | Autolus Limited | APRIL variants |
| CN110114371A (zh) | 2016-11-11 | 2019-08-09 | 奥托路斯有限公司 | 嵌合抗原受体 |
-
2015
- 2015-02-26 AU AU2015221933A patent/AU2015221933B2/en not_active Ceased
- 2015-02-26 EP EP15708871.7A patent/EP3110838B1/en active Active
- 2015-02-26 WO PCT/GB2015/050557 patent/WO2015128653A2/en not_active Ceased
- 2015-02-26 JP JP2016553489A patent/JP6556156B2/ja not_active Expired - Fee Related
- 2015-02-26 ES ES15708871T patent/ES2737690T3/es active Active
- 2015-02-26 US US15/121,644 patent/US10752665B2/en not_active Expired - Fee Related
- 2015-02-26 EP EP17172770.4A patent/EP3243831A1/en not_active Withdrawn
- 2015-02-26 CA CA2939411A patent/CA2939411A1/en not_active Abandoned
- 2015-02-26 CN CN201580010156.0A patent/CN106414502A/zh active Pending
-
2017
- 2017-05-26 US US15/606,660 patent/US10611811B2/en not_active Expired - Fee Related
- 2017-05-31 JP JP2017107701A patent/JP6707496B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-30 JP JP2019014039A patent/JP2019068855A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514787A5 (enExample) | ||
| Ramos et al. | In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas | |
| US20230081443A1 (en) | Anti-il1rap antibodies | |
| JP2016538830A5 (enExample) | ||
| Zhao et al. | Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential | |
| JP2017505622A5 (enExample) | ||
| JP2025032089A (ja) | 腫瘍微小環境を標的とするキメラ抗原受容体 | |
| Cook et al. | Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions | |
| JP2018508215A5 (enExample) | ||
| JP2017508466A5 (enExample) | ||
| JP2016537966A5 (enExample) | ||
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| Low et al. | Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen | |
| JP2020500542A5 (enExample) | ||
| PH12015500113A1 (en) | Anti-kit antibodies and uses thereof | |
| Larson et al. | Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma | |
| JP2017501129A5 (enExample) | ||
| Fichtner et al. | Alpaca (Vicugna pacos), the first nonprimate species with a phosphoantigen-reactive Vγ9Vδ2 T cell subset | |
| JP2017509342A5 (enExample) | ||
| JP2016196468A5 (enExample) | ||
| JP2017522903A5 (enExample) | ||
| JP2017526361A5 (enExample) | ||
| JP2018515474A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| WO2012103165A3 (en) | Anti-kit antibodies and uses thereof |